Top Page
Diagnos
(ADK)
Diagnos (ADK) vs. S&P 500 (SPY)
Diagnos Business Overview & Revenue Model
Diagnos Financial Statement Overview
| Breakdown | |||||
| TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 127.40K | 170.16K | 438.83K | 267.07K | 331.52K | 326.47K |
| Gross Profit | |||||
| -871.40K | 35.80K | -418.30K | -347.53K | -473.45K | -759.37K |
| EBIT | |||||
| -1.25M | -2.69M | -2.55M | -2.02M | -2.71M | -2.88M |
| EBITDA | |||||
| -3.04M | -2.45M | -2.10M | -2.45M | -1.93M | -2.94M |
| Net Income Common Stockholders | |||||
| -3.76M | -3.12M | -2.61M | -2.05M | -3.38M | -3.84M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 2.82M | 219.01K | 920.91K | 1.36M | 1.87M | 693.95K |
| Total Assets | |||||
| 3.20M | 663.79K | 1.54M | 1.95M | 2.43M | 1.21M |
| Total Debt | |||||
| 3.29M | 3.19M | 1.19M | 471.68K | 337.55K | 5.52M |
| Net Debt | |||||
| 3.22M | 2.97M | 764.86K | 112.29K | -232.89K | 5.38M |
| Total Liabilities | |||||
| 3.67M | 3.72M | 1.66M | 818.19K | 614.78K | 6.29M |
| Stockholders Equity | |||||
| -477.21K | -3.05M | -113.51K | 1.13M | 1.82M | -5.08M |
| Cash Flow | Free Cash Flow | ||||
| -3.00M | -2.16M | -2.07M | -1.40M | -2.66M | -2.36M |
| Operating Cash Flow | |||||
| -2.99M | -2.15M | -2.04M | -1.36M | -2.64M | -2.32M |
| Investing Cash Flow | |||||
| -2.56M | -14.02K | 503.52K | 262.93K | -759.98K | -96.47K |
| Financing Cash Flow | |||||
| 5.52M | 2.08M | 1.60M | 882.82K | 3.83M | 2.40M |
Diagnos Technical Analysis
Diagnos Peers Comparison
Diagnos Corporate Events
DIAGNOS has announced significant advancements in cybersecurity certification for its CARA System application, following extensive penetration tests aligned with Quebec Ministry of Health’s cybersecurity requirements. The positive assessment from the Cyber Defense Operations Center allows Quebec healthcare institutions to integrate the CARA system, marking a crucial step towards achieving ISO 27001 certification, which is progressing as planned with upcoming audits.
Spark’s Take on TSE:ADK Stock
According to Spark, TipRanks’ AI Analyst, TSE:ADK is a Underperform.
Diagnos is struggling with severe financial issues, characterized by persistent losses and negative equity. While recent corporate initiatives and expansions show potential for growth, the company’s current financial health and poor technical indicators heavily weigh down the stock’s attractiveness. Without significant improvements in profitability and operational efficiency, the stock remains high-risk.
To see Spark’s full report on TSE:ADK stock, click here.
Diagnos Inc. has announced an amendment to its convertible debentures, involving insider Mr. André Larente, who holds debentures valued at $20,000. The amendment, which does not require valuation or minority approval under MI 61-101 due to its limited market impact, has been approved by the board and awaits TSX Venture Exchange acceptance. This move is part of DIAGNOS’s strategy to align its financial operations with shareholder interests.
Spark’s Take on TSE:ADK Stock
According to Spark, TipRanks’ AI Analyst, TSE:ADK is a Underperform.
Diagnos is struggling with severe financial issues, characterized by persistent losses and negative equity. While recent corporate initiatives and expansions show potential for growth, the company’s current financial health and poor technical indicators heavily weigh down the stock’s attractiveness. Without significant improvements in profitability and operational efficiency, the stock remains high-risk.
To see Spark’s full report on TSE:ADK stock, click here.
Diagnos Inc. has announced that its application for a medical device license for its CARA System is now under active processing by Health Canada, following a period of backlog. This development is a significant step in the company’s growth strategy, as the CARA System is integral to its mission of providing advanced medical diagnostic solutions.
Spark’s Take on TSE:ADK Stock
According to Spark, TipRanks’ AI Analyst, TSE:ADK is a Underperform.
Diagnos struggles with severe financial challenges, marked by consistent losses and negative equity. While technical indicators suggest a neutral outlook, the stock remains under pressure due to a lack of profitability. Recent corporate initiatives provide some potential for growth, but the overall financial health and valuation remain significant concerns.
To see Spark’s full report on TSE:ADK stock, click here.
Diagnos Inc. has announced an amendment to the terms of its $120,000 unsecured convertible debentures, extending the maturity date from March 25, 2025, to March 25, 2026, and increasing the yearly interest rate from 8% to 10% for the extended period. This amendment is subject to TSX Venture Exchange acceptance and formal documentation, potentially impacting the company’s financial strategy and investor relations.
DIAGNOS has opened its first U.S. office in Fort Lauderdale, Florida, as part of its growth strategy to expand its reach in the ophthalmic and optometry sectors. This move aligns with its strategic vision of meeting client needs and is accompanied by plans to hire local employees. Additionally, DIAGNOS is working on obtaining US FDA certification for its AI-assisted fundus image analysis platform, which is expected to advance healthcare professionals’ ability to diagnose diabetic retinopathy, hypertensive retinopathy, and age-related macular degeneration. The company has also engaged DS Market Solutions Inc. to enhance market depth and liquidity for its securities, while announcing the resignation of board member Francis Bellido.
Diagnos Inc. has announced its filing for Saudi FDA authorization of its CARA SYSTEM, an AI-assisted medical device designed to assist healthcare professionals in detecting diabetic retinopathy, age-related macular degeneration, and hypertensive retinopathy. This strategic move, in collaboration with Kanhoor Medical, aims to enhance diagnostic accuracy and streamline workflows, marking a significant growth phase for Diagnos in the Saudi Arabian market, where diabetes prevalence is notably high.
Diagnos Inc. has announced an amendment to the terms of its unsecured convertible debentures, extending the maturity date from March 1, 2025, to March 1, 2026, and increasing the interest rate from 8% to 10% for the extended period. This amendment is subject to acceptance by the TSX Venture Exchange and aims to adjust financial terms to better align with market conditions, potentially impacting investor relations and financial strategy.
Diagnos Inc. has announced its filing for FDA pre-market authorization for its AI-powered CARA SYSTEM, designed to assist in the early detection of various eye diseases. The company has partnered with ORA, a leading clinical research organization, to navigate the U.S. regulatory landscape, marking a significant step in its expansion strategy and enhancing its market visibility.
DIAGNOS Inc. announced the closing of a private placement, raising $2,014,610.70 through the issuance of 6,715,369 units at $0.30 each. The proceeds will support product development and commercialization of AI-based screening services, regulatory affairs, and general operations. Each unit includes a share and a warrant, with warrants exercisable at $0.40 within 18 months. The completion of this placement is subject to regulatory approvals, and securities issued are under a hold period until June 6, 2025.
DIAGNOS Inc. announced the closing of a non-brokered private placement, raising gross proceeds of $2,014,611 through the issuance of over 6.7 million units at $0.30 per unit. Each unit comprises one common share and one warrant, exercisable at $0.40 for 18 months. The funds will support the development and commercialization of AI-based screening services, regulatory affairs, and general operations. The placement is subject to regulatory approvals and all issued securities are under a statutory hold period until June 6, 2025.
DIAGNOS announced receiving a financial contribution of up to $400,000 from the Canada Economic Development for Quebec Regions to support its international marketing strategy for the CARA project. This funding highlights the government’s recognition of DIAGNOS as a significant player in the Canadian economy, potentially enhancing its market position and expanding its global reach.
Diagnos Inc. announced its participation in The Microcap Conference 2025, aiming to showcase its AI-driven medical detection technology and engage with investors. The event is viewed as a strategic opportunity to enhance investor relations, particularly with U.S. investors, and to highlight potential growth milestones, including partnerships and expected deployments in 2025.